Acumen Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	53.99	35.63	66.89	130.1	122.16
Short-Term Investments	62.88	135.93	176.64	47.5	72.08
Cash & Short-Term Investments	116.87	171.56	243.52	177.61	194.24
Cash Growth	-31.88%	-29.55%	37.11%	-8.56%	343.70%
Other Current Assets	5.39	6.75	3.09	2.72	4.42
Total Current Assets	122.25	178.31	246.62	180.33	198.66
Net Property, Plant & Equipment	-	-	-	0.27	0.04
Long-Term Investments	-	59.97	62.55	15.84	31.62
Other Long-Term Assets	0.58	0.72	0.96	0.15	0.01
Total Assets	122.83	238.99	310.13	196.59	230.33
Accounts Payable	0.55	5.65	1.38	1.64	1.09
Accrued Expenses	20.69	21.96	10.84	6.07	4.06
Short-Term Debt	8.77	-	-	-	-
Current Portion of Leases	-	-	0.76	0.11	-
Total Current Liabilities	30.01	27.61	12.97	7.81	5.15
Long-Term Debt	22.4	29.42	29.9	-	-
Other Long-Term Liabilities	-	0.15	0.28	-	-
Total Long-Term Liabilities	22.4	29.57	30.18	-	-
Total Liabilities	52.4	57.18	43.15	7.81	5.15
Common Stock	0.01	0.01	0.01	0	0
Additional Paid-in Capital	516.8	506.99	489.45	359.95	352.98
Accumulated Other Comprehensive Income	0.08	-0.05	0.31	-0.75	-0.23
Retained Earnings	-446.46	-325.13	-222.8	-170.43	-127.57
Total Common Shareholders' Equity	70.43	181.82	266.97	188.78	225.18
Shareholders' Equity	70.43	181.82	266.97	188.78	225.18
Total Liabilities & Equity	122.83	238.99	310.13	196.59	230.33
Total Debt	31.16	29.42	30.65	0.11	0
Net Cash (Debt)	85.7	142.14	212.87	177.5	194.24
Net Cash Growth	-39.70%	-33.23%	19.93%	-8.62%	343.70%
Net Cash Per Share	1.42	2.37	4.38	4.37	9.68
Book Value	70.43	181.82	266.97	188.78	225.18
Book Value Per Share	1.16	3.03	5.49	4.65	11.23
Tangible Book Value	70.43	181.82	266.97	188.78	225.18
Tangible Book Value Per Share	1.16	3.03	5.49	4.65	11.23

Updated Mar 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q